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Angiotensin II does not acutely reverse the reduction of proteinuria by
long-term ACE inhibition. Angiotensin converting enzyme (ACE) inhib-
itors are known to lower urinary protein excretion in human renal
disease. This proteinuria lowering effect of ACE inhibition has been
hypothesized to be a result of renal hemodynamic changes due to the
inhibition of angiotensin II (Ang II) production. To test this hypothesis
we studied the short-term effects of different doses of exogenous Ang II
(5%, 10% and 20% of the pressor dose) on renal hemodynamics and
urinary protein excretion in comparison with placebo infusion in six
non-diabetic normotensive proteinuric patients, both before and after
three months treatment with the ACE inhibitor, lisinopril. Lisinopril
lowered proteinuria from 7.5 1.9 to 2,7 0.6 g124 hr and induced a fall
in blood pressure, renal vascular resistance and filtration fraction,
whereas plasma Ang II levels were similar to the pre-treatment values.
Ang II infusion induced typical effects which appeared to be similar
before and during lisinopril treatment: a dose-related fall in renal plasma
flow and rise in systemic blood pressure, renal vascular resistance and
filtration fraction, while the glomerular filtration rate remained rela-
tively stable. However, neither before nor during lisinopril therapy did
any changes in urinary protein loss occur during the infusions of Ang II,
despite the fact that Ang H reversed the long-term systemic and renal
hemodynamic changes induced by the ACE inhibitor. We conclude that
the long-term antiproteinuric effect of the ACE inhibitor, lisinopril, is
neither mediated through changes in circulatory Ang II levels nor
influenced by acute changes in systemic and renal hemodynamics,
suggesting a non-hemodynamic mechanism of action.
Angiotensin converting enzyme (ACE) inhibitors have been
shown to lower urinary protein excretion in patients with
different renal diseases [1—5]. The mechanism of this antipro-
teinuric effect is still debated. In many human [1—5] and animal
studies [6—10], it has been hypothesized that the antiproteinuric
effect of ACE inhibitors is related to their typical renal hemo-
dynamic effects that are the result of the inhibition of angioten-
sin II (Ang II) synthesis [11—14]. Although the role of a fall in
systemic blood pressure induced by ACE inhibition cannot be
ruled out, both human [3—5] and animal [6, 9] studies have
shown that blood pressure reduction as such did not affect
proteinuria. In favor of the 'Ang Il-dependent renal hemody-
namic' hypothesis are data from animal studies showing that
short-term exogenous Ang II infusion [15—19] or a rise in
endogenous Ang II levels [20] results in proteinuria, in associ-
ation with a rise in intraglomerular capillary pressure. These
effects on renal hemodynamics and protein excretion were
shown to be prevented or reversed by concomitant infusion of
the Ang II receptor blocker saralasin [17, 20]. Likewise, ACE
inhibition lowered established proteinuria in rats in association
with a fall in intraglomerular capillary pressure [7], and pre-
vented a rise in proteinuria in experimental renal diseases by
preventing the development of glomerular hypertension that
occurred in control animals [8—10]. However, recent animal
data question the role of renal hemodynamics and even the role
of Ang II as a key hormone in the mechanism of the antipro-
teinuric effect of ACE inhibition [21—23]. These data showed
that the beneficial effect of ACE inhibition in preventing pro-
teinuria in experimental renal disease can be attributed to
structural glomerular changes [22], and to amelioration of
permselectivity properties of the damaged glomerular capillary
wall [23]. In addition, such non-hemodynamic mechanism of
action may be mediated by effects of ACE inhibition on
hormonal systems other than the renin-angiotensin system,
such as the kallikrein-kinin system [24]. Whether one may
extrapolate these animal data to the human situation is ques-
tionable. In contrast to the data of experiments in rats [15—20],
Loon et al recently showed that infusion of a pressor dose of
Ang II in healthy and in proteinuric humans did not induce an
increase but rather caused a fall in urinary protein excretion,
probably due to a fall in glomerular filtration rate and thereby in
filtered protein load [25].
To date, no (animal or human) study has investigated the
effect of Ang II infusion on protein excretion during ACE
inhibition, thereby substituting the hormone that is supposed to
be inhibited. If Ang II infusion during ACE inhibition would
reverse both the antiproteinuric and renal hemodynamic effects
of the ACE inhibitor, this would favor an Ang Il-mediated renal
hemodynamic mechanism of the lowering of proteinuria. We
therefore studied the effects of different doses of exogenous
Ang 11(5%, 10% and 20% of the pressor dose) on urinary
protein excretion, renal hemodynamics and blood pressure in
proteinuric patients before and, especially, after lowering uri-
nary protein excretion with the ACE inhibitor, lisinopril.
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Patients and protocol
Six patients with chronic renal disease were enrolled in the
study: four male and two female. After all medication had been
withdrawn, all patients had a stable proteinuria of more than 3
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Table 1. Patient characteristic s at entry
Patient
no. Sex
Age
years Histology
Blood
pressure
mm Hg
Creatinine
clearance
mi/mm
Proteinuria
g/24 hr
I
2
3
4
5
6
F
M
M
F
M
M
43
31
39
31
58
38
mgp
IgA
mgp
mgp
fsgs
fsgs
118/72
136/80
125/69
127/70
128/74
132/78
87
100
143
128
117
143
4.8
4.1
16.7
7.3
6.6
5.2
Mean
SEM
128/74
3/2
120
9
7.5
1.9
Abbreviations are: F, female; M, male; mgp, membranous glomeru-
lopathy; IgA, IgA nephropathy; fsgs, focal segmental glomerulosclero-
sis.
grams per 24 hours with no or only minor edema, and all had a
normal blood pressure. The patient characteristics are given in
Table 1. A diet containing 50 mmol sodium and a fixed amount
of protein was prescribed throughout the whole study. The
study protocol was approved by the local medical ethical
committee. All patients gave their informed consent.
The study consisted of a control period of at least one month
without any medication, and an ACE inhibitor period in which
lisinopril (10 mg/day) was given for three months to obtain a
stable antiproteinuric effect. The lisinopril dose had to be
increased in two patients to 20 mg/day to achieve a more
pronounced reduction in urinary protein excretion. The patients
visited the outpatient clinic every two weeks. At each visit,
blood pressure was measured, as well as electrolytes, urea,
creatinine and protein in serum and in a 24-hour urine sample.
Both the control period and the ACE inhibitor period were
concluded by an Ang II infusion-study according to the follow-
ing protocol.
The patients were hospitalized for five days. Each day they
remained in sitting position from 7:30 a.m. to 5:30 p.m. The first
three days were included to stabilize blood pressure and protein
excretion. At noon on the third day the Ang II pressor dose was
determined. This was defined as the Ang II infusion dose
needed to induce a 20 mm Hg rise in diastolic blood pressure.
The actual study was carried out on days 4 and 5 with infusion
of respectively placebo (day 4) and Ang II (day 5). On these
days at 7:30 a.m. an oral fluid load and, in the ACE inhibitor
period, the lisinopril dose was given, as well as a bolus injection
of renal function tracers followed by a constant infusion of
tracers and fluid (dextrose 5%, 120 ml/hr). Every hour blood
was drawn, and every two hours urine was collected and a
standardized meal containing equal amounts of fluid, sodium,
potassium, carbohydrates and protein was given. The total
daily amounts equalled that of the diet consumed in the previ-
ous weeks and were kept stable during the whole study. Blood
pressure was recorded with an automated device (Dinamap')
every 10 minutes throughout the study days. The mean of the
values of each two-hour period was calculated. Baseline mea-
surements were performed from 9:30 to 11:30 a.m. followed by
three two-hour periods during which three different increasing
doses of placebo (day 4) or Ang II (day 5: respectively 5%, 10%
and 20% of the Ang II pressor dose as determined on day 3)
were infused. This resulted in a dose-response study of the
effects of Ang II (compared with placebo), ranging from sub-
pressor doses without effects on systemic blood pressure but
yet with renal effects, to moderate pressor doses with both
systemic and renal effects. The following data were obtained
during the four consecutive two-hour periods (baseline, 5%,
10% and 20% Ang II pressor doses or placebo infusion): plasma
Ang II level, blood pressure, glomerular filtration rate (GFR),
effective renal plasma flow (ERPF), and the urinary electrolytes
and protein excretion. In the last two-hour period of each
testday (thus during placebo and 20% Ang II pressor dose
infusion both in the control period and during lisinopril treat-
ment) the fractional urinary clearances of the two different-
sized proteins albumin (molecular weight 67,000 D) and IgG
(160,000 D) were also measured. By comparing equivalent
two-hour periods during the placebo infusion and the Ang II
infusion day, a possible bias introduced by circadian rhythmic
variation of the various parameters was corrected [26]. These
measurements were performed both during the control period
without medication and again after three months at the end of
the ACE inhibitor period.
Laboratory procedures
Serum and urinary electrolytes, urea and creatinine were
determined with an automated multi-analyzer (SMA-C, Tech-
nicon'), while urinary protein was determined in each urine
sample with a pyrogallol-red-molybdate method [27]. The day-
to-day variation of this method is less than 3%. Serum and
urinary albumin and IgG were measured with an ELISA, as
previously described [28]. In short, after appropriate dilution, a
three-step solid-phase sandwich technique with peroxidase-
labeled antibodies was used. To block non-specific binding
bovine serum albumin was used in the IgG assay and casein in
the albumin assay [291. Detection limits in these assays were 3
to 200 ng of protein per ml. All (urine or serum) samples of one
patient were determined within one assay plate, after storage at
—20°C. Coefficients of variation for the albumin and IgG assays
were 6.4% and 6.8%, respectively, in serum and 5.6% and 5.4%
in urine. Fractional clearances of IgG and albumin were calcu-
lated as fraction of the GFR measured by urinary iothalamate
clearance. Plasma for the Ang II level determination was drawn
in prechilled glass tubes containing phenylmethylsulfonyl-fluo-
ride, pepstatine A, I, lO-phenanthroline, captopril, neomycine
and EDTA to prevent in vitro generation or degradation of Ang
II. The blood was immediately chilled in ice and centrifugated
at 4°C. The plasma was stored at —20°C until analyzed. Ang II
was determined with a radioimmunoassay [30]. Cross reactivity
of the Ang II antibody with angiotensin I is less than 0.1% and
with angiotensin III 100%. The detection range of this assay is
2.5 to 200 fmol/ml with an intra-assay coefficient of variation of
5%. GFR and ERPF were measured according to a previously
described method using a constant infusion of '251-iothalamate
and '311-hippuran, respectively [31]. The day-to-day variation
of this method is 2.2% and 5.0%, respectively. Filtration
fraction (FF) was calculated as the ratio of GFR and ERPF.
Renal vascular resistance (RVR) was calculated as ratio of
mean arterial blood pressure measured during the renal function
studies and ERPF. Fractional proteinuria was calculated as the
urinary protein excretion per 100 ml GFR.
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Data analysis Table 2. Mean SEM values during two-hour baseline periods and
subsequent two hour infusions of 5%, 10% and 20% of placebo or
angiotensin II (Ang II) pressor doses on blood pressure and renal
parameters during the control period without treatment and
during the ACE inhibitor (lisinopril) period in six normotensive
proteinuric patients
Control period ACE inhibitor period
Placebo Ang II Placebo Ang IIInfusion dose
Plasma Ang II
pmoi/iiter
Baseline
5%
10%
20%
DBP mm Hg
Baseline
5%
10%
20%
ERPF mi/rn/n
Baseline
5%
10%
20%
GFR mi/rn/n
Baseline
5%
10%
20%
FF %
Baseline
5%
10%
20%
Results
18.3 4.0 21.6 3.7 25.2 3.6 24.7 5.6
19.0 3.8 20.6 4.0 18.2 3.5 25.6 1.5k
17.9 2.5 28.5 49 18.4 2.6 33.7 51a.b
15.6 1.8 29.3 6.9a 15.9 2.2 45.0 63a,b,c
76±3 74±2 632b 642b,
77±2 76±3 63÷3b 653b.c
76±3 78±3 643b 6g3b,c77 4 81 4 65 3b 73 4ac
514 68 517 67 550 54 552 31
509 67 488 63 543 42 493 25
522 68 482 68 528 39 431 25
540 69 460 64 573 42 404 23a,b
95±7 95±8 85±10 88±9
96±6 %±6 88±9 93±8
97±6 95±6 89±8 92±6
96±5 94±7 91±8 8g6b,c
15.6 14b
16.2 10b
17.0 1.0
16.0 1.0
15.8 12b
18.9 i.r
21.4 1.la
21.8 11a,b
149 14b
150 12b
156 12b
147 12b
147 11b,c
167 10
199 12
226 13a,b
1.7 0.4
3.6 1.6
5.2 2.1
6.2 2.1
4.2 1.6
5.5 1.3
3.7 1.2
2.3 07a,b
The data are given both as absolute values (mean standard
error; SEM) as measured during all four test days (Table 2), and
as placebo-corrected values (Fig. 1). Both during the control
period and during the ACE inhibitor period, the baseline values
obtained (from 9:30 to 11:30 a.m.) on the placebo- and the
corresponding Ang II infusion-day did not differ significantly for
any of the parameters. To correct the values obtained in the
three consecutive two-hour periods during Ang II infusion for
any change observed during placebo infusion, the changes
(compared to the baseline value) occurring on the placebo
infusion-day were subtracted from the time-corresponding val-
ues during the Ang II infusion-day. These placebo-corrected
values are given in Figure 1. The changes in these values during
the control period were then compared with those during the
ACE inhibitor period for each parameter, to evaluate whether
the effects due to the Ang II infusion were altered by the
lisinopril treatment. Statistical evaluation was carried out with
nonparametric tests, using Friedman's analysis of variance by
ranks for the repeated measurements within each study period,
and using Wilcoxon's signed ranks tests for paired comparisons
between the time-corresponding values obtained during the two
study periods. Statistical significance was assumed when the P
value was less than 5%.
During the control period the pressor dose of Ang II appeared
to be 17.1 3.4 ng/kglmin. As a consequence, the mean 5%, 19.5 1.6 19.1 1.5
10% and 20% Ang II pressor infusion rates were 0.9 0.2, 1.7 20.0 1.8 20.8 1.9
0.3 and 3.4 0.7 nglkglmin. These increasing doses of Ang
elicited characteristic effects on Ang II levels, blood pressure
19.7 1.8 21.2 2.2a
18.6 1.6 22.0 2.4a
and renal parameters, as shown in Table 2 (control period) and
Figure 1 (broken lines). Plasma Ang II levels rose compared to
baseline values on the 10% and 20% Ang II pressor dose, as did
diastolic blood pressure. Placebo-corrected values of systolic
RVR (1O-;
mm Hg/mi/mm)
Baseline 198 26 192 25
5% 201 24 209 27
10% 195 24 220 3l
blood pressure (not shown in the figure) increased from 125 3 20% 192 24 240 35
mm Hg in the baseline period to 126 4 (NS), 129 4 (P <
0.05) and 131 3 mm Hg (P < 0.05) on the 5%, 10% and 20% UNa mmoi/2 hrBaseline 3.2 0.9 4.5 1.1
Ang II pressor dose, respectively. A dose-related fall in ERPF 5% 3.4 1.0 3,1 0.9
was observed whereas no significant changes in GFR were
seen. Thus, a dose-related rise in FF and RYR occurred.
10% 4.6 1.2 2.5 0.7a
20% 4.6 1.1 1.9 o.sa
Urinary sodium excretion fell. However, Ang II infusion had no
significant effect on urinary protein excretion (Table 2, control
period, and Fig. 1, broken line). This was also true for fractional
total protein excretion, which was 4.6 0.9 mg/lOU ml GFR
during the baseline period and 4.8 1.4,4.6 1.1 and 3.8 0.8
mg/100 ml GFR (NS) during the 5%, 10% and 20% Ang
pressor dose infusion, respectively. Fractional clearances of
albumin and IgG measured during 20% placebo and 20% Ang I
pressor dose infusion did not significantly change either (Table
2, control period).
Three months of lisinopril treatment resulted in the expected
changes in the different parameters. Out-patient blood pressure
fell from 128 3/74 2 mm Hg in the control period to 115
4/65 3 mm Hg on lisinopril, and 24-hour urinary protein
excretion was reduced by 63 7% (range 49 to 94%), from a
mean of 7.5 1.9 g/24 hr before treatment to 2.7 0.6 g/24 hr
during lisinopril. Dietary sodium and protein intake had not
changed during lisinopril treatment compared with the pre-
Uprotein g/2 hr
Baseline 0.51 0.11 0.53 0.12 0.13 0.03" 0.11 0.03
5% 0.55 0.14 0.59 0.14 0.10 004b 0.10 004b,c
10% 0.59 0.15 0.59 0.13 0.14 0.04" 0.11
20% 0.67 0.17 0.61 0.15 0.16 0.05" 0.10 004b.c
Fr.cl.Alb. (10-i)
20% 127 40 112 37 30 15" 27 10L,
Fr.cl.IgG (l0-)
20% 13.1 6.0 12.3 4.9 2.2 1.0" 1.7 0.6lc
Abbreviations are: DBP, diastolic blood pressure; ERPF, effective
renal plasma flow; GFR, glomerular filtration rate; FF, filtration frac-
tion; RVR, renal vascular resistance; UNa, urinary sodium excretion;
u rotein' urinary protein excretion; Fr.cl.Alb., fractional clearance of
aigumin; Fr.cl.IgG, fractional clearance of IgG.
a p < 0.05 compared to the values during the corresponding placebo
infusion in the same study period
b P < 0.05 compared to the values during the corresponding placebo
infusion in the control period
C P < 0.05 compared to the values during corresponding Ang II
infusion in the control period
E>
z
82
78
E 74
S
a 70
66
62
0.14
0.7
0.6
0.5
0>
0.4
0.3
Q- 0.2
0.1
0
treatment values, as reflected by a stable total 24-hour urinary
excretion of sodium (66 17 and 76 15 mmol/day) and urea
(372 49 and 366 44 mmoLlday) in the control and lisinopril
period, respectively. As measured in the baseline periods of the
test days (Table 2, Fig. 1), ERPF rose by 13 10% (NS) during
lisinopril treatment, while FF fell by 16 6% and RVR by 19
7% (both P < 0.05). GFR had also fallen during lisinopril
treatment (though not significantly) by 8 5% versus control.
Proteinuria was reduced by 70 10% during lisinopril as
measured in the two-hour baseline periods of the test days, and
fractional protein excretion had fallen from 4.6 0.9 mg/l00 ml
GFR in the control period to 1.0 0.2 mg/100 ml GFR during
lisinopril (both P < 0.05). Fractional clearances of albumin and
IgG had decreased during ACE inhibition as shown by the
values obtained during the 20% placebo infusions (Table 2). The
numerally more pronounced fall in IgG clearance did not
significantly differ from the fall in fractional albumin clearance.
Despite these changes induced by the ACE inhibitor, the
plasma Ang II levels had not changed significantly after three
months of lisinopril treatment compared to the pretreatment
values, as is evident comparing the values measured during the
placebo-infusion test days (Table 2). In accordance with this,
the Ang II pressor dose had not changed significantly (from 17.1
3.4 nglkg/min in the control period to 15.9 2.4 ngfkglmin
during lisinopril treatment). Mean 5%, 10%, and 20% Ang II
pressor doses were therefore virtually similar to those in the
control period: 0.8 0.1, 1.6 0.2 and 3.2 0.5 nglkg/min,
respectively. These infusion rates resulted in Ang II plasma
levels that appeared to be higher, in particular on the 20% Ang
II pressor dose (Table 2, ACE inhibitor period, and Fig. 1, solid
line) than during Ang II infusions in the control period. The
effects of Ang II on blood pressure and renal parameters in the
ACE inhibitor period were, however, quite similar compared to
the effects of Ang II infusions in the control period. Again, a
clear Ang II dose-related rise in diastolic blood pressure, FF
and RVR was observed, as well as a fall in ERPF and natriure-
sis (Table 2, ACE inhibitor period, and Fig. 1, solid lines).
Similarly, a rise in placebo-corrected values of systolic blood
pressure occurred from ill 5 mm Hg in the baseline period to
114 5(Ns), 115 4(Ns)and 118 4mniHg(P<0.05)onthe
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Fig. 1. Effects of increasing doses of Ang II (5%, 10%
and 20% of the pressor dose) during the control period
(broken lines) and the ACE inhibitor period (solid lines)
on plasma angiotensin II (Ang II) levels, diastolic blood
pressure (DBP), effective renal plasma flow (ERPF),
glomerular filtration rate (GFR), filtration fraction (FF),
renal vascular resistance (RVR), and urinary sodium
(UNV) and protein excretion, The data (mean
5EM) are corrected for the effects of placebo infusions
(Methods). *O < 0.05 The effect of Ang II infusion
compared with the baseline value of the same study
period. +P < 0.05 The value during the ACE inhibitor
period (solid lines) compared with the time-
corresponding value in the control period (broken lines).
6
4
2
0
—2
.4
Base- 5% 10% 20%
line AnglI Angil AnglI
Base- 5% 10% 20%
line Angli Angli Angil
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5%, 10% and 20% Ang II pressor doses, respectively. GFR fell
upon the 20% Ang II pressor dose during the ACE inhibitor
period, whereas no significant changes occurred during the 5%
and 10% Ang II pressor dose. It is of importance to note that
already at a 5% or 10% Ang II pressor dose, all the ACE
inhibitor-induced changes in renal hemodynamics were com-
pletely reversed as the values of ERPF, GFR, FF and RVR
reached or exceeded the baseline and placebo values of the
control period (Table 2, Fig. 1). Moreover, the 20% Ang II
pressor dose infusion during lisinopril treatment reversed the
blood pressure lowering effect of the ACE inhibitor as diastolic
and systolic blood pressures were then no longer significantly
different from the pretreatment values. Despite these systemic
and renal hemodynamic effects, Ang II infusion during lisinopril
therapy had, like in the control period, no effect on protein
excretion (Table 2, ACE inhibitor period, Figure 1, solid line).
This was true for each of the six patients. Fractional protein
excretion during lisinopril treatment did not change significantly
either during Ang II infusion: 1.0 0.2 mg/100 ml GFR during
the baseline period and 1.4 0.4, 1.0 0.6 and 1.0 0.5
mgIlOO ml GFR during 5%, 10% and 20% Ang II pressor dose
infusion, respectively. Fractional clearances of albumin and
IgG did not change either during the 20% Ang II pressor dose
infusion (Table 2, ACE inhibitor period).
When comparing the data obtained in the control and the
ACE inhibitor period, generally no shifts were noticed in the
Ang II dose-response curves (Fig. 1, compare broken and solid
lines). The effects of similar doses of Ang II on diastolic and
systolic blood pressure, FF, RVR, natriuresis and urinary
protein excretion were not significantly different during ACE
inhibition compared with the control period. However, the
responses of ERPF and GFR to Ang II infusion were more
pronounced in the ACE inhibitor period than in the control
period: The fall in ERPF during Ang II infusion was greater (P
< 0.05), and GFR fell during Ang II infusion in the ACE
inhibitor period, whereas it did not change during Ang II
infusion in the control period (difference P < 0.05). This
seemingly increased sensitivity to Ang II during ACE inhibition
may, however, be accounted for by the simultaneously higher
plasma Ang II levels obtained in the ACE inhibitor period.
Discussion
It has been demonstrated, in human [1—5] and animal [6, 7]
studies, that established proteinuria may be reduced by ACE
inhibitors. The mechanism of this antiproteinuric effect of ACE
inhibition, which is still debated, has been related to the specific
renal hemodynamic effects due to the inhibition of angiotensin
II (Ang II) synthesis by these agents [1—10]. The present study
is the first to show that Ang II infusion during ACE inhibition,
substituting the hormone that is supposed to be inhibited, does
offset the hemodynamic effects without reversing the antipro-
teinuric effect of the ACE inhibitor. These findings question,
firstly, the role of (circulatory) Ang II as the key hormone in the
antiproteinuric effect of ACE inhibition. Secondly, they ques-
tion the role of ACE inhibitor-induced systemic and renal
hemodynamic changes in the antiproteinuric effect, since (at
least) short-term hemodynamic changes did not affect the
lowering of proteinuria by ACE inhibition.
The renal hemodynamic effects of Ang II in our proteinuric
patients are in accordance with previous observations in normal
and hypertensive humans [12, 13, 25, 32, 33] and animals [11, 14,
16—20, 34], as well as in patients with the nephrotic syndrome
[25]. The typical fall in renal plasma flow associated with a rise
in filtration fraction (and renal vascular resistance) while gb-
merular filtration rate remains relatively stable (depending on
the dose of Ang II and the rise occurring in blood pressure)
suggests a rise in glomerular capillary pressure due to a pre-
dominantly postglomerular Ang Il-induced vasoconstriction
[11, 14, 35, 36]. Such an Ang Il-induced rise in glomerular
capillary pressure has been shown to lead to glomerular perm-
selectivity changes with an increased urinary protein loss in rats
[16—20]. However, although Ang II may induce proteinuria
through a hemodynamic mechanism in rats, Gasse et al [34] and
Loon et a! [25] found no proteinuric effect of Ang II infusion in
dogs and in humans, respectively. The results of the Ang II
infusions in the present study, as obtained in the pretreatment
control period, confirm the latter findings: the Ang Il-induced
renal hemodynamic effects are not associated with a rise in
proteinuria. The discrepancy with the effects of Ang II on
protein excretion in rats could be due to the much higher doses
of Ang II (with strong pressor effects) used in most of these
studies [15—18]. However, also lower doses of Ang II induced
proteinuria in rats [19, 20]. More important may be that all of
these data were obtained in anesthetized rats, which could well
have affected the response to exogenous Ang II. Lastly, a
species difference may be responsible for the observed discrep-
ancy.
Whatever the effect of Ang II infusion on urinary protein
excretion may be in the untreated (control) animal and human,
the goal of the present study was to investigate whether the
antiproteinuric effect of ACE inhibition is caused by renal
hemodynamic changes as a result of a reduction in Ang II
synthesis. To that purpose, we studied the effect of Ang II
infusion after reducing proteinuria with the ACE inhibitor,
lisinopril. It could well have been that in such an 'Ang II-
deprived state' which was presumed to be responsible for the
reduction in protein excretion, infusion of Ang II would induce
a rise in protein excretion and reverse the antiproteinuric effect
of the ACE inhibitor. Three months of ACE inhibition with
lisinopril resulted in a clear fall in proteinuria and typical
hemodynamic changes in all our patients. This quantitative
change in proteinuria was accompanied by qualitative changes,
since lisinopril induced a numerally greater fall in IgG clearance
compared to the reduction in albumin clearance. However, this
difference did not reach statistical significance. Previously, we
have demonstrated in a larger group of patients, studying the
clearances of different-sized endogenous proteins, that lisino-
pril indeed improves the size selectivity of the glomerular
filtration barrier [28]. As far as the typical hemodynamic
changes are concerned, lisinopril induced a fall in blood pres-
sure, a slight rise in ERPF and fall in GFR with a more
pronounced fall in FF and RVR, suggesting a fall in intraglo-
merular capillary pressure by a predominantly postglomerular
vasodilation as has been shown in animals [7, 11]. These
hemodynamic effects of ACE inhibition are the opposite of
those induced by Ang II, which is in accordance with the idea
that they are the result of a reduction in Ang II levels [11—14].
Ang II infusions during lisinopril treatment reversed the ACE
inhibitor-induced systemic and renal hemodynamic changes
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effectively in our proteinuric patients, the latter even at sub-
pressor doses, as has been shown before in other patient groups
[12, 13] and in animals [11, 14]. Nevertheless, the infusions of
Ang II had no effect on urinary protein excretion, neither
quantitatively nor qualitatively, in any of our patients, and did
thus not reverse the antiproteinuric effect of the ACE inhibitor.
Does this intriguing observation, that Ang II reverses the
hemodynamic effects of ACE inhibition without affecting the
reduction in proteinuria, prove that the antiproteinuric effect of
ACE inhibition is not mediated through Ang Il-mediated renal
hemodynamic effects? This question cannot be answered defi-
nitely before several alternative explanations have been inves-
tigated. First of all, it could still be that the antiproteinuric effect
of ACE inhibition is indirectly related to the renal hemody-
namic effects. It may be that only long-term sustained ACE
inhibitor-induced changes in the glomerular inicrocirculation
reduce protein leakage through the capillary wall, such as by
structural changes that are not reversed by the short-term (6
hour) hemodynamic effects during the Ang II infusions. Inter-
estingly, we have previously observed that an optimal antipro-
teinuric effect of lisinopril is only reached after several weeks of
treatment [4], whereas the systemic and renal hemodynamic
effects are known to occur within hours. However, ACE
inhibition has also been shown to lower urinary protein excre-
tion acutely or in a few days, both in rats [6, 7] and in humans
[2, 37—39] in association with its short-term renal hemodynamic
effects. One could hypothesize that the short-term effects of
ACE inhibition on proteinuria are hemodynamically mediated,
whereas the long-term effects are mediated by structural
changes. The latter could still be the result of the long-term
hemodynamic effects, or, alternatively, be the result of non-
hemodynamic Ang 11-mediated effects of ACE inhibition.
The second explanation could be that the Ang II infusion
protocol was inadequately designed to substitute Ang II at all
'ACE-inhibited' and 'Ang 11-deprived' effector sites. Indeed, one
could even question whether any 'Ang lI-deprived state' was
actually achieved during ACE inhibition, as we found that the
plasma levels of Ang II as well as the pressor responses to Ang II
had not significantly changed after three months of lisinopril
treatment. This notwithstanding the ACE inhibitor induced
changes in blood pressure, renal hemodynamics and proteinuria.
Such a phenomenon of sustained hemodynamic effects of long-
term ACE inhibition, whereas plasma Ang II levels after an initial
fall return to pre-treatment values, has been described before [2,
40-45]. It supported the concept that for the sustained effects of
ACE inhibition the effects on tissue Ang II may be of more
importance than the effects on circulatory Ang II [46]. As such,
plasma Ang II levels probably do not reflect the rate of Ang II
synthesis in the extravascular renal tissue [47]. Inhibition of this
renal tissue Ang II production could well be responsible for the
antiproteinuric effect of ACE inhibition. Exogenous Ang II infu-
sion of only six hours, as performed in the present study, may
have been insufficient to penetrate the renal tissue adequately to
reach the extravascular effector sites. Indeed, such a phenomenon
has been shown recently in healthy dogs using virtually the same
Ang II infusion rates as in our patients [48]. One could speculate
that renal tissue Ang II could influence the glomerular perniselec-
tivity to proteins independently of the hemodynamic effects, such
as by regulating the contraction of mesangial cells [36, 49, 50] or
by inducing changes in structure or electrical charge of the
glomerular filtration barrier due to influences on glomerular
mesangial, endothelial or visceral epithelial cells [50]. Ang II has
been found to be a growth stimulating factor [51, 52], and it has
been shown that ACE inhibition can prevent vascular hypertro-
phy [53, 54]. Inhibition of tissue Ang II formation might reduce
hypertrophy and extracellular matrix formation in the glomerulus,
thereby improving glomerular barrier function and proteinuria [22,
23]. To date all these interesting alternatives are still speculative.
Whatever the mechanism may be, our data show that the working
hypothesis, suggesting a direct link between the inhibition of Ang
II synthesis and the resulting renal hemodynamic changes on the
one hand and the reduction in proteinuria on the other, is at least
questionable. Our new hypothesis would be that the short-term
effects of ACE inhibition on proteinuria are hemodynamically
mediated by inhibition of circulatory Ang II synthesis, whereas
the long-term effects are mediated by tissue Ang II and its
structural effects on the glomerular filtration barrier. The above-
mentioned time dependency of the antiproteinuric effect of ACE
inhibition, which, after an acute onset becomes maximal only after
several weeks of treatment, could well fit with this hypothesis.
Lastly, it may be that the proteinuria lowering effect of ACE
inhibition is not at all mediated through Ang II. In that case this
effect may be caused by the potentiation of other hormone
systems than the renin-angiotensin system, such as the kallikrein-
kinin system, as has recently been shown in rats [24]. However,
previous studies using saralasin [17, 20] as well as preliminary
studies in rats using a specific Ang II antagonist (DuP 753), show
similar actions as ACE inhibitors, including a lowering of intra-
glomerular pressure and a reduction of proteinuria in experimental
renal disease [55, 56]. These data argue once more for a role of
Ang II in the antiproteinuric effect of ACE inhibition. It is unlikely
that stimulation of the prostaglandin production by ACE inhibition
is the mechanism of action, since it was shown recently that
inhibition of prostaglandin synthesis adds to the antiproteinuric
effect of both captopril and lisinopril instead of reducing it [38, 57].
In conclusion, the present study demonstrates that the mech-
anism of the antiproteinuric effect of ACE inhibition is not
likely to be the direct result of Ang Il-mediated renal hemody-
namic effects. Exogenous Ang II and its short-term systemic
and renal hemodynamic effects, which are compatible with a
rise in intraglomerular pressure, do not influence protein excre-
tion in humans, and do not affect the chronic antiproteinuric
effect of ACE inhibition. It remains to be clarified whether this
is also true for the acute antiproteinuric effect of ACE inhibitor
therapy, and whether the chronic effect is related to long-term
effects of ACE inhibition on glomerular hemodynamics or to
non-hemodynamic mechanisms. Moreover, the question arises
whether the effect of ACE inhibition is mediated through
inhibition of renal tissue Ang II formation or to interference in
other hormonal systems than the renin-angiotensin system,
such as the kinin system. Future human studies investigating
the short- and long-term effects of ACE inhibition, with longer
lasting (intrarenal) Ang II infusions or with agents that more
specifically inhibit components of the renin-angiotensin system,
such as renin inhibitors and Ang II antagonists, should be
performed to establish whether Ang II should still be consid-
ered to be the key hormone that determines the antiproteinuric
effect of ACE inhibition.
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